Analysis Tools
mortality/aging
|
• mice administered tamoxifen at P1 show lethality beginning at P12
• lethality is not due to failure to thrive
• however, mice treated with tamoxifen between 2 and 4 months of age show no effect on overall survival up to 8 weeks later and show no differences in viability up to 36 weeks later
|
cardiovascular system
|
• mice treated with tamoxifen at P1 show thin and fragile appearing cerebral vessels
• however, vessel density within the brain at P21 is normal
|
|
• more than 50% of mice treated with tamoxifen between 2 and 4 months develop brain arteriovenous malformations within 8 weeks of treatment
• however, mice treated with tamoxifen at P1 do not exhibit cortical brain arteriovenous malformations and cerebral vessels do not appear dilated
|
|
• mice administered tamoxifen at P1 that survive to P21 show an incompletely penetrant (11 of 32 mice) phenotype of focal intracranial hemorrhage
• however, mice treated with tamoxifen at P1 do not show hemorrhage in the intestines, lung, or liver at P14
• however, mice treated with tamoxifen between 2 and 4 months do not show hemorrhage 8 weeks after treatment
|
nervous system
|
• mice treated with tamoxifen at P1 show thin and fragile appearing cerebral vessels
• however, vessel density within the brain at P21 is normal
|
|
• mice administered tamoxifen at P1 that survive to P21 show an incompletely penetrant (11 of 32 mice) phenotype of focal intracranial hemorrhage
• however, mice treated with tamoxifen at P1 do not show hemorrhage in the intestines, lung, or liver at P14
• however, mice treated with tamoxifen between 2 and 4 months do not show hemorrhage 8 weeks after treatment
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| arteriovenous malformations of the brain | DOID:0060688 |
OMIM:108010 |
J:312482 | |
